News for ARDS Stock

Aridis Provides Corporate Update Aridis Provides Corporate Update Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024 Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report® on Bloomberg TV Aridis Pharmaceuticals Announces $2 Million Offering Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301 Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R) Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K Aridis Provides Corporate Update Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients Interviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money Report(R) Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP) New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25 (Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates RedChip Interviews Aridis Pharmaceuticals' CEO Vu Truong Aridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7 Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission Aridis Pharmaceuticals CEO Discusses Monoclonal Antibody Cocktail Protection Against COVID-19 Omicron Variant and Other Viruses in Fox Business Interview Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses Aridis Pharmaceuticals Announces Third Quarter 2021 Results Aridis Pharmaceuticals Announces Second Quarter 2021 Results Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC) Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant Aridis Pharmaceuticals Announces First Quarter 2021 Results Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report® Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 Aridis Pharmaceuticals Announces Third Quarter 2020 Results /C O R R E C T I O N -- Aridis Pharmaceuticals, Inc./ Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501 Aridis Pharmaceuticals to Present at Upcoming Investor Conferences Aridis Pharmaceuticals Announces Second Quarter 2020 Results Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19 Aridis Pharmaceuticals to Discuss APEX™ in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer